Drug importation proposals threaten one drug maker more than others
States and others won’t be importing every single medicine — and some drug makers have far more to lose than others if the plans are finalized.
Related Articles
Supreme Court to hear challenge to ACA rule requiring free preventive care, cancer screenings
The Supreme Court will hear a challenge of preventive health care coverage mandated by the Affordable Care Act. The ruling could affect millions of Americans.
Vaccine advisory panel recommends expanded RSV use, and two new vaccines
The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus.
Makary says FDA will remove pharma representatives from advisory panels
Representatives from pharma and other industries already play a more limited role in advising the FDA.
GSK blood cancer therapy, once pulled from the market, is approved in the U.K.
GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was withdrawn several years ago.
Find COVID-19 guidance for your community
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Health care industry, worried millions could lose ACA insurance, pushes for Trump to delay changes
Hospitals and health insurers are alarmed at the prospect of an increase in the number of people without health insurance.
Medical journal receives U.S. attorney letter seeking information about alleged bias
“Why would the interim US attorney be qualified to judge scientific viewpoints on the treatment of advanced lung disease and critical illness?”
NIH said to have halted awarding of new grants to more top universities
Universities whose NIH funding has been frozen may face further strain as the agency holds off awarding new grants to at least a half dozen…
Medical journal receives U.S. attorney letter seeking information about alleged bias
“Why would the interim US attorney be qualified to judge scientific viewpoints on the treatment of advanced lung disease and critical illness?”
Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with